Coffee By the Bucket Better for Blood Pressure than By the Cup - CME Teaching Brief® - MedPage Today

Coffee By the Bucket Better for Blood Pressure than By the Cup - CME Teaching Brief® - MedPage Today: "Women who drink coffee by the pot full for a long time had a lower relative risk of hypertension than did women who indulged in one to three daily cups, Cuno S.P.M. Uiterwaal, M.D., of the University Medical Center, Utrecht, and colleagues, reported in the March issue of the American Journal of Clinical Nutrition. "

Novel Anticoagulant May Sidestep Bleeding Risk - CME Teaching Brief® - MedPage Today

ACC: Novel Anticoagulant May Sidestep Bleeding Risk - CME Teaching Brief® - MedPage Today: "NEW ORLEANS, March 25 -- An investigational oral thrombin receptor antagonist led to a trend toward reduced fatal and non-fatal cardiac events, with a low bleeding risk, in a phase II trial of patients with percutaneous coronary interventions, mostly stenting.

In the early results on the safety of SCH 530348, the first oral thrombin receptor antagonist, there was a slight but not statistically significant increase in major and minor bleeding events -- 4% versus 3.3% for placebo -- with a 40-mg dose. In further trials, 40 mg is the investigational dose that is expected to be pursued."

Dark Chocolate Improves Vascular Function - CME Teaching Brief® - MedPage Today

ACC: Dark Chocolate Improves Vascular Function - CME Teaching Brief® - MedPage Today: "EW ORLEANS, March 25 -- A cup of cocoa in the morning may improve endothelial function for overweight patients, a small study confirmed, particularly if the dark chocolate powder is mixed with unsweetened water. "

Clinical Characteristics andUtilization of Biochemical Markers in Acute Coronary Syndromes

http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.107.182882v1

Acute coronary syndrome (ACS)8 refers to a constellation of clinical symptoms caused by acute myocardial ischemia1,2. Owing to their higher risk for cardiac death or ischemic complications, patients with ACS must be identified among the estimated 8 million patients with nontraumatic
chest symptoms presenting for emergency evaluation each year in the US3. In practice, the terms suspected or possible ACS are often used by medical personnel early in the process of evaluation to describe patients for whom the symptom complex is consistent with ACS but the diagnosis has not yet been conclusively established./.../

Analytical Issues for Biochemical Markers of Acute Coronary Syndromes

Acute Coronary Syndromes and Heart Failure

High-Risk Lipid Abnormalities in Children and Adolescents. A Scientific Statement From the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, Wi

Drug Therapy of High-Risk Lipid Abnormalities in Children and Adolescents. A Scientific Statement From the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, Wi: "High-Risk Lipid Abnormalities in Children and Adolescents"
Despite compliance with lifestyle recommendations, some children and adolescents with high-risk hyperlipidemia will require lipid-lowering drug therapy, particularly those with familial hypercholesterolemia. The purpose of this statement is to examine new evidence on the association of lipid abnormalities with early atherosclerosis, discuss challenges with previous guidelines, and highlight results of clinical trials with statin therapy in children and adolescents with familial hypercholesterolemia or severe hypercholesterolemia. Recommendations are provided to guide decision-making with regard to patient selection, initiation, monitoring, and maintenance of drug therapy.

Drug Therapy of High-Risk Lipid Abnormalities in Children and Adolescents.

Abstract--Despite compliance with lifestyle recommendations, some children and adolescents with high-risk hyperlipidemia will require lipid-lowering drug therapy, particularly those with familial hypercholesterolemia. The purpose of this statement is to examine new evidence on the association of lipid abnormalities with early atherosclerosis, discuss challenges with previous guidelines, and highlight results of clinical trials with statin therapy in children and adolescents with familial hypercholesterolemia or severe hypercholesterolemia. Recommendations are provided to guide decision-making with regard to patient selection, initiation, monitoring, and maintenance of drug therapy

Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women: 2007 Update

Worldwide, cardiovascular disease (CVD) is the largest single cause of death among women, accounting for one third of all deaths.¹ In many countries, including the United States, more women than men die every year of CVD, a fact largely unknown by physicians.^2,3 The public health impact of CVD in women is not related solely to the mortality rate, given that advances in science and medicine allow many women to survive heart disease. For example, in the United States, 38.2 million women (34%) are living with CVD, and the population at risk is even larger.² In China, a country with a population of approximately 1.3 billion, the age-standardized prevalence rates of dyslipidemia and hypertension in women 35 to 74 years of age are 53% and 25%, respectively, which underscores the enormity of CVD as a global health issue and the need for prevention of risk factors in the first place.⁴ As life expectancy continues to increase and economies become more industrialized, the burden of CVD on women and the global economy will continue to increase.⁵ The human toll and economic impact of CVD are difficult to overstate. In the United States alone, $403 billion was estimated to be spent in 2006 on health care or in lost productivity as a result of CVD, compared with $190 billion for cancer and $29 billion for human immunodeficiency virus (HIV).² In addition to population-based and macroeconomic interventions, interventions in individual patients are key to reducing the incidence of CVD globally.⁶ Prevention of CVD is paramount to the health of every woman and every nation. Even modest control could have an enormous impact. It is projected that a reduction in the death rate due to chronic diseases by just 2% over 1 decade would prevent 36 million deaths.⁶

Statin use and risk of 10 Cancers

[Original Article]
Coogan, Patricia F.*; Rosenberg, Lynn*; Strom, Brian L.†‡
From the *Slone Epidemiology Center, Boston University, Boston, Massachusetts; †Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, Center for Education and Research on Therapeutics, and ‡Division of General Internal Medicine of the Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.
Submitted 16 May 2006; accepted 13 November 2006.
Supported by grant R01 CA45762 from the National Cancer Institute.
Editors’ note: A commentary on this article appears on page 194.
Correspondence: Patricia F. Coogan, Slone Epidemiology Center, 1010 Commonwealth Ave., Boston, MA 02215. E-mail: pcoogan@bu.edu
Abstract
Background: Statins affect the proliferation, survival, and migration of cancer cells, and it is thought that they may have chemopreventive properties in humans. The purpose of the present study was to evaluate the association between statin use and various types of cancer in our hospital-based case–control surveillance study.
Methods: Data were collected from patients ages 40–79 years who were admitted to participating hospitals in 3 centers in Philadelphia, New York, and Baltimore from 1991 to 2005. Nurses administered questionnaires to obtain information on medication use and other factors. We compared patients who had any of 10 types of cancer (a total of 4913 patients) with controls admitted for noncancer diagnoses (3900 patients). The following cancers were examined individually: female breast (n = 1185), prostate (n = 1226), colorectal (n = 734), lung (n = 464), bladder (n = 240), leukemia (n = 254), pancreas (n = 220), kidney (n = 226), endometrial (n = 220), and non-Hodgkin lymphoma (n = 144). Logistic regression models were used to estimate odds ratios and 95% confidence intervals among regular statin users compared with never-users.
Results: Odds ratios were compatible with 1.0 for all cancer types. For the 4 largest cancer sites (breast, prostate, colorectum, and lung), odds ratios did not vary significantly by duration of statin use.
Conclusions: Statins are among the most commonly used medications, and durations of use are increasing. The present data do not support either positive or negative associations between statin use and the occurrence of 10 cancer types. Cancer incidence should continue to be monitored among statin users.

guidelines for cardiovascular disease prevention in women

De: Marcelo Colominas [mailto:mgcolominas@gigared.com]
Enviada em: terça-feira, 6 de março de 2007 13:15
Para: Undisclosed-Recipient:;
Assunto: Revisión (AHA) de guías de prevención CV en la mujer

Review of the American Heart Association’s guidelines for cardiovascular disease prevention in women

J H Mieres

Correspondence to:
Jennifer H Mieres
MD, North Shore University Hospital, 300 Community Drive, Manhasset, NY 11030, USA; jmieres@nshs.edu

Cardiovascular disease (CVD) is the leading cause of death of women in the United States and most of the developed world. The latest available data from the World Health Organization indicate that 16.6 million people around the globe die of CVD each year. World deaths from coronary heart disease (CHD) in 2002 totalled 7.2 million. One in seven women in Europe will die of CHD; in the United Kingdom > 1.2 million women are living with CHD. Despite advances in diagnosing and treating CHD, the disease accounts for the majority of CVD deaths in women in the United States, with more than 240 000 dying annually. Although coronary heart disease is the predominant cause of mortality for adult women in the United States, screening for coronary risk factors and coronary risk reduction interventions remains underused in women. In February of 2004, the American Heart Association published the first evidence-based guidelines for CVD prevention in women, consisting of a set of clinical recommendations tailored to a woman’s individual level of risk.

Risco Cardiometabólico

Caro amigo: publiquei no site da SBD http://www.diabetes.org.br/ a matéria abaixo:

Risco Cardiometabólico: Uma Visão que Integra Endocrinologistas e Cardiologistas Reginaldo Albuquerque - 02/03/2007 13:21 editor científico do site da SBDMédicos endocrinologistas e cardiologistas estão começando a entender melhor as importantes conexões entre as doenças cardiovasculares e o diabetes. Isto se deve às descobertas de novos mecanismos fisiopatológicos que estão presentes nas duas situações, tais como as lesões no endotélio dos vasos. Estas lterações são decorrentes do "stress oxidativo", da obesidade, da má alimentação, da ipertensão arterial e até mesmo de infecções provenientes de lesões dentárias. Esta nova compreensão levou à criação de um novo conceito denominado "Risco Cardiometabólico". Risco cardiometabólico diz respeito a um conjunto de causas que representam potenciais fatores de risco que são alvos potenciais para um tratamento preventivo. A despeito de muitos avanços na prevenção e tratamento das doenças cardiovasculares (DCV), elas continuam como a principal causa de morte em muitos países desenvolvidos. De acordo com o estudo Hational Health and Nutrition Examination Survey (NHANES), realizado entre 1999-2002, 972.000 americanos morreram de doenças relacionadas com DCV em 2002.Acredita-se que neste estudo 224000 mortes foram causadas por diabetes do tipo 2. O NHANES 1999-2002 documentou um aumento de prevalência de diabetes e obesidade e acredita-se que estas duas situações estão intimamente relacionadas com as mortes devidas às DCV. Entre 1976 e 2002 o número de pessoas com obesidade, definida como um IMC acima de 30 kg/m2 dobrou passando de 15% para 30%. A obesidade é o o mecanismo primário tanto para o desenvolvimento do diabetes como para as doenças cardiovasculares. Estas duas condições tem vários fatôres comuns como: resistência à insulina,hipertensão e dislipemia. Quando estes fatores de risco ocorrem simultâneamente falamos em síndrome metabólica.(SM)O que é Risco Cardiometabólico. Os Riscos Cardiometábolicos compreendem os componentes da SM e muitos outros alvos que, somente agora, estão sendo descobertos e que até recentemente não eram levados em consideração. As consequências de um tratamento sub-ótimo são largamente conhecidas pelos sistemas de saúde em várias partes do mundo. O têrmo risco cardiometabólico é definido como um conjunto (cluster) de fatores de risco modificáveis e diversos marcadores que estão presentes em alguns indíviduos com maior risco de infarto do miocárdio, doença cérebro vascular e doença arterial periférica. Estas alterações incluem: hipertensão arterial, resistência à insulina, hipertensão, elevação do LDL-C e TG,baixa do HDL-C, obesidade abdominal, microalbuminúria e alterações da função endotelial.Associação dos Fatores de RiscoOs fatores de risco cardiometabólico tendem a se associar formando um conglomerado de modo que raramente uma pessoa tem apenas 1 ou 2 fatores. Meigs e colegas fizeram uma clássica descrição deste conceito "associativo" num dos trabalhos com a população de Framignham.
Ele indentificou três fatores para o agrupamento destas variáveisO primeiro círculo, no meio do diagrama, representa a associação do níveis de insulina,TG e HDL-C,IMC e a razão quadril-cintura, todos os quais são associados com a SM.O segundo círculo é a combinação dos níveis de glicose e insulina, que são associados com a intolerância à glicose.O terceiro círculo inclue os valores de pressão sistólica e diastólica e mais o IMC que estão associados com a hipertensão. Como pode se ver no diagrama há uma sobreposição destes círculos mostrando uma associação destes vários fatôres: o metabólico, o inflamatório e a pressão arterial. Com este reconhecimento, as Associações de Cardiologistas e Diabetes, estão divulgando repetidamente, que existe algo mais do que tratar isoladamente da hipertensão, do coração, do colesterol, das glicemias ou da hemoglobina glicada. É preciso pensar mais longe e incorporar com mais rapidez estes conhecimentos à prática médica beneficiando milhões de pessoas que sofrem destas situações. A diminuição da inércia clínica e a melhoria dos indicadores da atenção médica, certamente, terão um grande impacto nos custos e na qualidade de vida da população que sofre com as doenças cardiovasculares. Em janeiro deste ano, a Associação Americana de Diabetes e a Associação Americana do Coração divulgaram mais uma das suas diretrizes médicas, relacionadas a este assunto e que podem ser lidas na revista Diabetes Care 30,162-171, Janeiro de 2007, que em resumo sugere: "endocrinologistas prestem mais atenção ao controle da PA dos seus clientes, cardiologistas olhem mais além do coração"Diabetes CareCardiology

Comentários dos leitores
Rafael Ferreira da Silva - 03-03-2007 15:45:13
Dr. Reginaldo de Holanda! Parabéns pela ótima matéria, onde a cada dia conhecemos um pouco mais por meio de artigos científicos do diabetes. Rafael - Brasília/DF. Medley S/A Indústria Farmacêutica.
Nossa resposta: Rafael: grato pelos seus comentários. Reginaldo Albuquerque - editor do site

Caffeine May Prevent Heart Disease Death In Elderly

Caffeine May Prevent Heart Disease Death In Elderly
Main Category: Seniors / Aging News
Article Date: 27 Feb 2007 - 7:00 PST
Habitual intake of caffeinated beverages provides protection against heart disease mortality in the elderly, say researchers at SUNY Downstate Medical Center and Brooklyn College.

Using data from the first federal National Health and Nutrition Examination Survey Epidemiologic Follow-up Study, the researchers found that survey participants 65 or more years old with higher caffeinated beverage intake exhibited lower relative risk of coronary vascular disease and heart mortality than did participants with lower caffeinated beverage intake.

John Kassotis, MD, associate professor of medicine at SUNY Downstate, said, "The protection against death from heart disease in the elderly afforded by caffeine is likely due to caffeine's enhancement of blood pressure."

The protective effect also was found to be dose-responsive: the higher the caffeine intake the stronger the protection. The protective effect was found only in participants who were not severely hypertensive. No significant protective effect was in patients below the age of 65.

No protective effect was found against cerebrovascular disease mortality - death from stroke - regardless of age.

neurological_disorders_report

Los trastornos neurológicos afectan a millones de personas en todo el mundo: informe de la OMS

27 DE FEBRERO DE 2007 | BRUSELAS/GINEBRA -- Según un nuevo informe de la Organización Mundial de la Salud (OMS), los trastornos neurológicos (desde la epilepsia y la enfermedad de Alzheimer o los accidentes cerebrovasculares hasta el dolor de cabeza) afectan en todo el mundo a unos mil millones de personas. Entre los trastornos neurológicos figuran también los traumatismos craneoencefálicos, las infecciones neurológicas, la esclerosis múltiple, y la enfermedad de Parkinson.

En el informe Neurological Disorders: Public health challenges (que próximamente se traducirá al español) se pone de manifiesto que en todo el mundo están afectadas unos mil millones de personas, 50 millones sufren epilepsia, y 24 millones padecen Alzheimer y otras demencias. Los trastornos neurológicos afectan a personas de todos los países, sin distinción de sexos, niveles de educación ni de ingresos.

Angina, “Normal” Coronary Angiography, and Vascular Dysfunction: Risk Assessment Strategies

PLoS Medicine - Angina, “Normal” Coronary Angiography, and Vascular Dysfunction: Risk Assessment Strategies
associated with coronary arteries that appear “normal.” Normal is defined here as no visible disease or luminal irregularities (less than 50%) as judged visually at coronary angiography. Normal angiography in patients with chest pain is five times more common in women than in men [1]. Among patients with chest pain and normal angiography, an unknown number are suffering from cardiac pain of ischemic origin. Uncertainty is often difficult to allay, for medical attendants as well as for patients, resulting in perpetuation of symptoms, difficulties in management, and establishment of risk of subsequent coronary events [2]. In this article, we discuss how to stratify risk in patients with chest pain and a normal coronary angiogram. We based our article on a literature review, using the key words “angina with normal angiography,” “angina with normal coronary arteries,” “non-obstructive coronary disease,” or “chest pain of non-cardiac origin,” plus “[a]etiology,” “pathophysiology,” “diagnosis,” “classification,” “prognosis,” or “therapy.” A longer, more detailed version of this paper is found in the supplementary file S1.

Use of Nonsteroidal Antiinflammatory Drugs. An Update for Clinicians. A Scientific Statement From the American Heart Association -- Antman et al., 10.1161/CIRCULATIONAHA.106.181424 -- Circulation

Use of Nonsteroidal Antiinflammatory Drugs. An Update for Clinicians. A Scientific Statement From the American Heart Association -- Antman et al., 10.1161/CIRCULATIONAHA.106.181424 -- Circulation
Clinical trial data have prompted questions about the degree to which patients and their physicians should consider an increased risk of cardiovascular or cerebrovascular events when selecting medications for pain relief. Since the 2005 publication of a Science Advisory on the use of nonsteroidal antiinflammatory drugs (NSAIDs) by the American Heart Association,1 several important events have occurred that have served as the catalyst for this update for clinicians. (1) Additional data from randomized controlled trials of cyclooxygenase (COX)-2–selective agents have been reported and summarized in meta-analyses, which has reinforced the concern about cardiovascular events with COX-2 inhibitors (coxibs; Figure 1). (2) Several reports have appeared that have identified an increased risk of cardiovascular events even with the nonselective NSAIDs, which has raised concern about the use of those agents as well (Table). (3) Regulatory authorities in several regions of the world have introduced warning statements and advisories to both healthcare professionals and the lay public about the use of various NSAIDs (Figures 2 and 3)./.../

Distribuição espacial da mortalidade por infarto agudo do miocárdio no Município do Rio de Janeiro, Brasil

O objetivo deste estudo é analisar a distribuição espacial da mortalidade por infarto agudo do miocárdio no Município do Rio de Janeiro, Brasil. Foram analisados dados sobre mortalidade por infarto agudo do miocárdio ocorrido em 2000, por meio do Sistema de Informação de Mortalidade. Utilizou-se o modelo bayesiano empírico de suavização a fim de minimizar a variabilidade aleatória dos coeficientes de mortalidade associada ao tamanho das unidades geográficas de análise. A distribuição dos óbitos por infarto agudo do miocárdio na cidade é heterogênea e obedece a um padrão espacial associado a um forte gradiente social. O padrão de sub-risco de mortalidade por infarto agudo do miocárdio observado na Zona Oeste não condiz com o perfil de desigualdade social e de acesso aos serviços de saúde observado na área. Acredita-se que o risco de morrer por infarto agudo do miocárdio foi subestimado em função da alta proporção de óbitos por causa mal definida na área. O padrão espacial de mortalidade apresentou uma concentração do risco de morrer de infarto nas áreas mais pobres da cidade. As diversas unidades de saúde apresentam áreas de influência para o atendimento ao infarto agudo do miocárdio.

Quotes: Geoffrey Rose

Quotes: Geoffrey Rose

In the Stent Era, Heart Bypasses Get a New Look - New York Times

In the Stent Era, Heart Bypasses Get a New Look - New York Times
After more than a decade-long decline, is heart bypass surgery poised for a comeback?

Reconsidering Heart Bypass Surgery Some doctors say it may be time to give bypass operations a second look, including some cardiologists who specialize in the far more popular alternative — using stents to keep coronary arteries propped open.

No one is predicting a sudden surge back to bypass, which is still a far more invasive and initially riskier way to treat plaque-clogged heart arteries, a condition that afflicts millions of Americans.

The effect of statin therapy on infection-related mortality in patients with atherosclerotic diseases.

De: Marcelo Gustavo Colominas [mailto:mgcolominas@hotmail.com]
Enviada em: sexta-feira, 23 de fevereiro de 2007 23:35

The effect of statin therapy on infection-related mortality in patients with atherosclerotic diseases.
Crit Care Med. 2007 Feb;35(2):372-8. Related Articles, Links

Almog Y, Novack V, Eisinger M, Porath A, Novack L, Gilutz H.

Medical Intensive Care Unit, Soroka University Medical Center, Beer-Sheva, Israel.

OBJECTIVE: Statins have pleiotropic effects that are independent of their lipid-lowering ability. We have previously shown that prior statin therapy is associated with a decreased risk of severe sepsis in patients admitted with acute bacterial infection. The aim of this study was to determine whether statin therapy is associated with a decreased risk of infection-related mortality. DESIGN: A prospective, observational, population-based study. SETTING: Tertiary university medical center. PATIENTS: Using a computerized database, 11,490 patients with atherosclerotic diseases were identified and followed for up to 3 yrs. Two groups of patients were compared: those receiving statins in the final month before follow-up termination and those who were not. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: The primary outcome was infection-related mortality. Of the 11,362 patients included in the final analysis, 5,698 (50.1%) belonged to the statin group. Median follow-up was 19.8 months (interquartile range, 14.3-33.3). The risk of infection-related mortality was significantly lower in the statin compared with the no-statin group (0.9% vs. 4.1%), reflecting a relative risk of 0.22 (95% confidence interval, 0.17-0.28). Stepwise Cox proportional hazard survival analysis including a propensity score for receiving statins revealed that the protective effect of statins adjusted for all known potential confounders remained highly significant (hazard ratio, 0.37; 95% confidence interval, 0.27-0.52). CONCLUSIONS: Therapy with statins may be associated with a reduced risk of infection-related mortality. This protective effect is independent of all known comorbidities and dissipates when the medication is discontinued. If this finding is supported by prospective controlled trials, statins may play an important role in the primary prevention of infection-related mortality.

PMID: 17205009 [PubMed - in process]

Recommendations for the Standardization and Interpretation of the Electrocardiogram. Part I:

(Texto completo, bem como da parte II, a disposição para quem me enviar mensagem solicitandouma copia *pdf)
Recommendations for the Standardization and Interpretation of the Electrocardiogram. Part I: The Electrocardiogram and Its Technology. A Scientific Statement From the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology
Paul Kligfield MD, FAHA, FACC, Leonard S. Gettes MD, FAHA, FACC, James J. Bailey MD, Rory Childers MD, Barbara J. Deal MD, FACC, E. William Hancock MD, FACC, Gerard van Herpen MD, PhD, Jan A. Kors PhD, Peter Macfarlane DSc, David M. Mirvis MD, FAHA, Olle Pahlm MD, PhD, Pentti Rautaharju MD, PhD, and Galen S. Wagner MD

Abstract--This statement examines the relation of the resting ECG to its technology. Its purpose is to foster understanding of how the modern ECG is derived and displayed and to establish standards that will improve the accuracy and usefulness of the ECG in practice. Derivation of representative waveforms and measurements based on global intervals are described. Special emphasis is placed on digital signal acquisition and computer-based signal processing, which provide automated measurements that lead to computer-generated diagnostic statements. Lead placement, recording methods, and waveform presentation are reviewed. Throughout the statement, recommendations for ECG standards are placed in context of the clinical implications of evolving ECG technology.

siesta for a healthy heart -

Embrace your siesta for a healthy heart - International Herald Tribune: "Could midday napping save your life?

If the experience of Greek men is any guide, the answer just may be yes.

In a study released yesterday, researchers at the Harvard School of Public Health and in Athens reported that Greeks who took regular 30-minute siestas were 37 percent less likely to die of heart disease over a six-year period than those who never napped. The scientists tracked more than 23,000 adults, finding that the benefits of napping were most pronounced for working men.

Researchers have long recognized that Mediterranean adults die of heart disease at a rate lower than Americans and Northern Europeans. Diets rich in olive oil and other heart-healthy foods have received some of the credit, but scientists have been intrigued by the potential role of napping.

The study, published in the Archives of Internal Medicine, concluded that napping was more likely than diet or physical activity to lower the incidence of heart attacks and other life-ending heart ailments."